NOVO NORDISK A/S-B (NOV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:NOV - DK0062498333 - Common Stock
52.92 EUR
+4.14 (+8.49%)
We assign a fundamental rating of 6 out of 10 to NOV. NOV was compared to 53 industry peers in the Pharmaceuticals industry. While NOV belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. NOV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year NOV was profitable.
- NOV had a positive operating cash flow in the past year.
- Each year in the past 5 years NOV has been profitable.
- In the past 5 years NOV always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 20.26%, NOV belongs to the best of the industry, outperforming 98.11% of the companies in the same industry.
- NOV has a Return On Equity of 61.08%. This is amongst the best in the industry. NOV outperforms 94.34% of its industry peers.
- NOV has a better Return On Invested Capital (38.03%) than 98.11% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for NOV is significantly above the industry average of 14.02%.
- The last Return On Invested Capital (38.03%) for NOV is well below the 3 year average (50.29%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| ROIC | 38.03% |
ROA(3y)23.77%
ROA(5y)24.99%
ROE(3y)71.81%
ROE(5y)69.89%
ROIC(3y)50.29%
ROIC(5y)49.64%
1.3 Margins
- The Profit Margin of NOV (32.88%) is better than 100.00% of its industry peers.
- NOV's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 42.03%, NOV belongs to the top of the industry, outperforming 94.34% of the companies in the same industry.
- In the last couple of years the Operating Margin of NOV has grown nicely.
- NOV has a Gross Margin of 82.05%. This is amongst the best in the industry. NOV outperforms 84.91% of its industry peers.
- In the last couple of years the Gross Margin of NOV has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.03% | ||
| PM (TTM) | 32.88% | ||
| GM | 82.05% |
OM growth 3Y4.3%
OM growth 5Y1.69%
PM growth 3Y0.84%
PM growth 5Y1.73%
GM growth 3Y0.72%
GM growth 5Y0.24%
2. Health
2.1 Basic Checks
- NOV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for NOV has been reduced compared to 1 year ago.
- The number of shares outstanding for NOV has been increased compared to 5 years ago.
- NOV has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 4.65 indicates that NOV is not in any danger for bankruptcy at the moment.
- The Altman-Z score of NOV (4.65) is better than 60.38% of its industry peers.
- The Debt to FCF ratio of NOV is 1.66, which is an excellent value as it means it would take NOV, only 1.66 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 1.66, NOV belongs to the best of the industry, outperforming 88.68% of the companies in the same industry.
- NOV has a Debt/Equity ratio of 0.52. This is a neutral value indicating NOV is somewhat dependend on debt financing.
- NOV has a better Debt to Equity ratio (0.52) than 64.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 1.66 | ||
| Altman-Z | 4.65 |
ROIC/WACC6.19
WACC6.14%
2.3 Liquidity
- NOV has a Current Ratio of 0.78. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.78, NOV is not doing good in the industry: 84.91% of the companies in the same industry are doing better.
- A Quick Ratio of 0.57 indicates that NOV may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.57, NOV is doing worse than 79.25% of the companies in the same industry.
- The current and quick ratio evaluation for NOV is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 10.05% over the past year.
- NOV shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.54% yearly.
- Looking at the last year, NOV shows a quite strong growth in Revenue. The Revenue has grown by 16.64% in the last year.
- NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.94% yearly.
EPS 1Y (TTM)10.05%
EPS 3Y29.71%
EPS 5Y22.54%
EPS Q2Q%-26.47%
Revenue 1Y (TTM)16.64%
Revenue growth 3Y27.29%
Revenue growth 5Y18.94%
Sales Q2Q%5.14%
3.2 Future
- The Earnings Per Share is expected to grow by 5.49% on average over the next years.
- The Revenue is expected to grow by 6.10% on average over the next years.
EPS Next Y4.79%
EPS Next 2Y0.88%
EPS Next 3Y2.8%
EPS Next 5Y5.49%
Revenue Next Year7.98%
Revenue Next 2Y4.04%
Revenue Next 3Y4.95%
Revenue Next 5Y6.1%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.96, the valuation of NOV can be described as correct.
- NOV's Price/Earnings ratio is a bit cheaper when compared to the industry. NOV is cheaper than 73.58% of the companies in the same industry.
- NOV's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.47.
- With a Price/Forward Earnings ratio of 17.17, NOV is valued on the expensive side.
- NOV's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NOV is cheaper than 66.04% of the companies in the same industry.
- NOV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.96 | ||
| Fwd PE | 17.17 |
4.2 Price Multiples
- 71.70% of the companies in the same industry are more expensive than NOV, based on the Enterprise Value to EBITDA ratio.
- NOV's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.83 | ||
| EV/EBITDA | 10.94 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of NOV may justify a higher PE ratio.
PEG (NY)3.54
PEG (5Y)0.75
EPS Next 2Y0.88%
EPS Next 3Y2.8%
5. Dividend
5.1 Amount
- NOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:NOV (1/16/2026, 7:00:00 PM)
52.92
+4.14 (+8.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners33.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap235.15B
Revenue(TTM)315.60B
Net Income(TTM)103.77B
Analysts71.88
Price Target54.95 (3.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend1.33
Dividend Growth(5Y)16.56%
DP49.88%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.09%
Min EPS beat(2)-7.04%
Max EPS beat(2)-1.15%
EPS beat(4)2
Avg EPS beat(4)0.81%
Min EPS beat(4)-7.04%
Max EPS beat(4)7.46%
EPS beat(8)5
Avg EPS beat(8)1.75%
EPS beat(12)8
Avg EPS beat(12)1.59%
EPS beat(16)11
Avg EPS beat(16)1.6%
Revenue beat(2)0
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)0.55%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)6.95%
Revenue beat(8)3
Avg Revenue beat(8)0.61%
Revenue beat(12)6
Avg Revenue beat(12)0.51%
Revenue beat(16)9
Avg Revenue beat(16)0.77%
PT rev (1m)-1.84%
PT rev (3m)-15.31%
EPS NQ rev (1m)-1.77%
EPS NQ rev (3m)-9.84%
EPS NY rev (1m)-0.49%
EPS NY rev (3m)-4.03%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-8.7%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-2.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.96 | ||
| Fwd PE | 17.17 | ||
| P/S | 5.57 | ||
| P/FCF | 28.83 | ||
| P/OCF | 14.19 | ||
| P/B | 10.34 | ||
| P/tB | 27.75 | ||
| EV/EBITDA | 10.94 |
EPS(TTM)3.12
EY5.9%
EPS(NY)3.08
Fwd EY5.82%
FCF(TTM)1.84
FCFY3.47%
OCF(TTM)3.73
OCFY7.04%
SpS9.51
BVpS5.12
TBVpS1.91
PEG (NY)3.54
PEG (5Y)0.75
Graham Number18.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| ROCE | 47.73% | ||
| ROIC | 38.03% | ||
| ROICexc | 43.08% | ||
| ROICexgc | 76.17% | ||
| OM | 42.03% | ||
| PM (TTM) | 32.88% | ||
| GM | 82.05% | ||
| FCFM | 19.31% |
ROA(3y)23.77%
ROA(5y)24.99%
ROE(3y)71.81%
ROE(5y)69.89%
ROIC(3y)50.29%
ROIC(5y)49.64%
ROICexc(3y)60.7%
ROICexc(5y)59.32%
ROICexgc(3y)124.92%
ROICexgc(5y)112.44%
ROCE(3y)63.71%
ROCE(5y)65.35%
ROICexgc growth 3Y-1.28%
ROICexgc growth 5Y0.46%
ROICexc growth 3Y-2.16%
ROICexc growth 5Y-9.95%
OM growth 3Y4.3%
OM growth 5Y1.69%
PM growth 3Y0.84%
PM growth 5Y1.73%
GM growth 3Y0.72%
GM growth 5Y0.24%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 1.66 | ||
| Debt/EBITDA | 0.58 | ||
| Cap/Depr | 290.66% | ||
| Cap/Sales | 19.91% | ||
| Interest Coverage | 53.02 | ||
| Cash Conversion | 80.23% | ||
| Profit Quality | 58.73% | ||
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 4.65 |
F-Score4
WACC6.14%
ROIC/WACC6.19
Cap/Depr(3y)294.05%
Cap/Depr(5y)277.71%
Cap/Sales(3y)14.25%
Cap/Sales(5y)13.08%
Profit Quality(3y)89.38%
Profit Quality(5y)87.75%
High Growth Momentum
Growth
EPS 1Y (TTM)10.05%
EPS 3Y29.71%
EPS 5Y22.54%
EPS Q2Q%-26.47%
EPS Next Y4.79%
EPS Next 2Y0.88%
EPS Next 3Y2.8%
EPS Next 5Y5.49%
Revenue 1Y (TTM)16.64%
Revenue growth 3Y27.29%
Revenue growth 5Y18.94%
Sales Q2Q%5.14%
Revenue Next Year7.98%
Revenue Next 2Y4.04%
Revenue Next 3Y4.95%
Revenue Next 5Y6.1%
EBIT growth 1Y6.92%
EBIT growth 3Y32.76%
EBIT growth 5Y20.94%
EBIT Next Year18.56%
EBIT Next 3Y8.09%
EBIT Next 5Y8.99%
FCF growth 1Y-21.68%
FCF growth 3Y13.52%
FCF growth 5Y14.4%
OCF growth 1Y16.27%
OCF growth 3Y30.05%
OCF growth 5Y20.93%
NOVO NORDISK A/S-B / NOV.DE FAQ
What is the fundamental rating for NOV stock?
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.
Can you provide the valuation status for NOVO NORDISK A/S-B?
ChartMill assigns a valuation rating of 4 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.
What is the profitability of NOV stock?
NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for NOV stock?
The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to grow by 4.79% in the next year.
Is the dividend of NOVO NORDISK A/S-B sustainable?
The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 0 / 10 and the dividend payout ratio is 49.88%.